001     1050467
005     20260112202640.0
024 7 _ |a 10.1016/j.expneurol.2025.115604
|2 doi
024 7 _ |a 0014-4886
|2 ISSN
024 7 _ |a 1090-2430
|2 ISSN
024 7 _ |a 10.34734/FZJ-2026-00236
|2 datacite_doi
037 _ _ |a FZJ-2026-00236
082 _ _ |a 610
100 1 _ |a Blaschke, Stefan J.
|0 P:(DE-Juel1)186027
|b 0
245 _ _ |a Subacute cathodal transcranial direct current stimulation rescues secondary thalamic neurodegeneration after cortical stroke in mice
260 _ _ |a Amsterdam [u.a.]
|c 2026
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1768229506_25760
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Transcranial direct current stimulation (tDCS) is a clinically promising neuromodulatory therapy, capable of promoting function and motor recovery after stroke. Beyond the primary stroke lesion, remote networks disturbances, e.g., stroke-induced secondary neurodegeneration (SND), are related to long-term disabilities. Under the hypothesis that tDCS promotes recovery by supporting neuroprotection, we investigated the effects of tDCS on thalamic SND after stroke. Three days after cortical stroke, induced by photothrombosis, cathodal tDCS over the lesioned cortex was performed daily for ten days (39.6 kC/m2). SND, i.e., neuronal loss, and inflammation in the ipsilesional thalamus were evaluated ex vivo 28 days after stroke. Parameters of functional thalamic network integration measured by resting-state functional magnetic resonance imaging (rs-fMRI) were conducted longitudinally. To assess the effects of tDCS on glucose metabolism, positron emission tomography (PET) was performed after a similar tDCS regimen in healthy mice. Repetitive tDCS decreased the ipsilateral thalamic glucose metabolism in unlesioned animals. Four weeks after cortical stroke, secondary glial scaring was found in the ipsilesional thalamus, its extent correlating to the cortical lesion size (R2 = 0.54, p < 0.001). Notably, while it did not affect glial scaring, tDCS reduced thalamic neurodegeneration by over 60 % (p < 0.05), being reflected by parameters of functional thalamic integration as assessed by rs-fMRI. Additionally, tDCS downregulated the pro-inflammatory polarization of microglia. Overall, tDCS ameliorated the stroke-induced remote SND, in parallel to mitigating sustained neuroinflammation. Thus, the data show that tDCS exerts previously unknown effects on remote brain regions after stroke.Keywords: Experimental stroke; Glucose metabolism; Neuroinflammation; Secondary neurodegeneration; Stroke recovery; Transcranial direct current stimulation.
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Backes, Heiko
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Vlachakis, Susan
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Rautenberg, Nora
|0 P:(DE-Juel1)188381
|b 3
700 1 _ |a Demir, Seda
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Wiedermann, Dirk
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Aswendt, Markus
|0 P:(DE-Juel1)196051
|b 6
700 1 _ |a Fink, Gereon R.
|0 P:(DE-Juel1)131720
|b 7
700 1 _ |a Schroeter, Michael
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Rueger, Maria A.
|0 P:(DE-HGF)0
|b 9
|e Corresponding author
773 _ _ |a 10.1016/j.expneurol.2025.115604
|g Vol. 398, p. 115604 -
|0 PERI:(DE-600)1466932-8
|p 115604 -
|t Experimental neurology
|v 398
|y 2026
|x 0014-4886
856 4 _ |u https://juser.fz-juelich.de/record/1050467/files/1-s2.0-S0014488625004698-main.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:1050467
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)131720
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2026
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-31
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EXP NEUROL : 2022
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-31
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-31
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-31
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EXP NEUROL : 2022
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-31
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-31
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-31
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21